Lung Adenocarcinoma - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 120 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lung Adenocarcinoma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Lung Adenocarcinoma - Pipeline Review, H1 2015', provides an overview of the Lung Adenocarcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Lung Adenocarcinoma Overview 9
Therapeutics Development 10
Pipeline Products for Lung Adenocarcinoma - Overview 10
Pipeline Products for Lung Adenocarcinoma - Comparative Analysis 11
Lung Adenocarcinoma - Therapeutics under Development by Companies 12
Lung Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 14
Lung Adenocarcinoma - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Lung Adenocarcinoma - Products under Development by Companies 18
Lung Adenocarcinoma - Products under Investigation by Universities/Institutes 20
Lung Adenocarcinoma - Companies Involved in Therapeutics Development 21
Amgen Inc. 21
Astex Pharmaceuticals, Inc. 22
AstraZeneca PLC 23
AVEO Pharmaceuticals, Inc. 24
Axelar AB 25
Bayer AG 26
BioNumerik Pharmaceuticals, Inc. 27
Boehringer Ingelheim GmbH 28
DiNonA Inc. 29
Eisai Co., Ltd. 30
Genentech, Inc. 31
Genmab A/S 32
Immunomedics, Inc. 33
Incyte Corporation 34
Medisyn Technologies, Inc. 35
Pfizer Inc. 36
Sanofi 37
VG Life Sciences, Inc. 38
Vichem Chemie Research Ltd. 39
Lung Adenocarcinoma - Therapeutics Assessment 40
Assessment by Monotherapy Products 40
Assessment by Combination Products 41
Assessment by Target 42
Assessment by Mechanism of Action 45
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
4-B4 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
afatinib - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
AV-203 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AXL-1717 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
AZD-6738 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BAY-1163877 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Adenocarcinoma - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
dacomitinib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
DBPR-112 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
dimesna - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
hydroxychloroquine + sorafenib tosylate - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Interferon Lambda-1 Linked Fab Dimer - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
lenvatinib - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MAG-Tn3 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
MT-477 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ruxolitinib phosphate - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SAR-408701 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecule for Cancer - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecule to Inhibit EGFR for Oncology - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
SNX-5422 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
solitomab - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Stem Cell Therapy for Oncology - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
TdCyd - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
TF-011 Monomethyl Auristatin E - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Vaccine for Lung Adenocarcinoma - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
Lung Adenocarcinoma - Recent Pipeline Updates 93
Lung Adenocarcinoma - Dormant Projects 118
Appendix 119
Methodology 119
Coverage 119
Secondary Research 119
Primary Research 119
Expert Panel Validation 119
Contact Us 119
Disclaimer 120

List of Tables

Number of Products under Development for Lung Adenocarcinoma, H1 2015 10
Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 13
Number of Products under Investigation by Universities/Institutes, H1 2015 14
Comparative Analysis by Late Stage Development, H1 2015 15
Comparative Analysis by Clinical Stage Development, H1 2015 16
Comparative Analysis by Early Stage Development, H1 2015 17
Products under Development by Companies, H1 2015 18
Products under Development by Companies, H1 2015 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2015 20
Lung Adenocarcinoma - Pipeline by Amgen Inc., H1 2015 21
Lung Adenocarcinoma - Pipeline by Astex Pharmaceuticals, Inc., H1 2015 22
Lung Adenocarcinoma - Pipeline by AstraZeneca PLC, H1 2015 23
Lung Adenocarcinoma - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 24
Lung Adenocarcinoma - Pipeline by Axelar AB, H1 2015 25
Lung Adenocarcinoma - Pipeline by Bayer AG, H1 2015 26
Lung Adenocarcinoma - Pipeline by BioNumerik Pharmaceuticals, Inc., H1 2015 27
Lung Adenocarcinoma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 28
Lung Adenocarcinoma - Pipeline by DiNonA Inc., H1 2015 29
Lung Adenocarcinoma - Pipeline by Eisai Co., Ltd., H1 2015 30
Lung Adenocarcinoma - Pipeline by Genentech, Inc., H1 2015 31
Lung Adenocarcinoma - Pipeline by Genmab A/S, H1 2015 32
Lung Adenocarcinoma - Pipeline by Immunomedics, Inc., H1 2015 33
Lung Adenocarcinoma - Pipeline by Incyte Corporation, H1 2015 34
Lung Adenocarcinoma - Pipeline by Medisyn Technologies, Inc., H1 2015 35
Lung Adenocarcinoma - Pipeline by Pfizer Inc., H1 2015 36
Lung Adenocarcinoma - Pipeline by Sanofi, H1 2015 37
Lung Adenocarcinoma - Pipeline by VG Life Sciences, Inc., H1 2015 38
Lung Adenocarcinoma - Pipeline by Vichem Chemie Research Ltd., H1 2015 39
Assessment by Monotherapy Products, H1 2015 40
Assessment by Combination Products, H1 2015 41
Number of Products by Stage and Target, H1 2015 43
Number of Products by Stage and Mechanism of Action, H1 2015 46
Number of Products by Stage and Route of Administration, H1 2015 49
Number of Products by Stage and Molecule Type, H1 2015 51
Lung Adenocarcinoma Therapeutics - Recent Pipeline Updates, H1 2015 93
Lung Adenocarcinoma - Dormant Projects, H1 2015 118